ARTVArtiva Biotherapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Artiva Biotherapeutics, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARTVEsta | $420M#2 | — | 1.2x#1 | — | -100.0%#4 | -28.3%#3 | — | -24.1%#1 | — | — | 262.7%#1 | — |
| RGNX | $527M#1 | — | 7.3x#3 | 3.1x#2 | 104.5%#2 | 14.6%#2 | -94.6%#2 | -270.2%#3 | — | — | -13.9%#3 | — |
| XFOR | $349M#3 | 2.5x#2 | 2.2x#2 | 10.0x#3 | 1273.2%#1 | -111.5%#4 | -247.4%#3 | -50.9%#2 | -582.0%#1 | — | — | — |
| AGEN | $325M#4 | 2.4x#1 | — | 2.8x#1 | 10.4%#3 | 98.7%#1 | -17.7%#1 | — | — | — | 61.5%#2 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice